US20220081405A1 - Method for preparing diselenide compound - Google Patents

Method for preparing diselenide compound Download PDF

Info

Publication number
US20220081405A1
US20220081405A1 US17/290,894 US202017290894A US2022081405A1 US 20220081405 A1 US20220081405 A1 US 20220081405A1 US 202017290894 A US202017290894 A US 202017290894A US 2022081405 A1 US2022081405 A1 US 2022081405A1
Authority
US
United States
Prior art keywords
compound
dihydroflavonol
diselenide
preparing
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US17/290,894
Other versions
US11618741B2 (en
Inventor
Kunyuan Song
Weiwei Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Aiqi Pharmaceutical Technology Co Ltd
Original Assignee
Shanghai Aiqi Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Aiqi Pharmaceutical Technology Co Ltd filed Critical Shanghai Aiqi Pharmaceutical Technology Co Ltd
Assigned to SHANGHAI SPARK PHARMACEUTICAL CO., LTD. reassignment SHANGHAI SPARK PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEN, WEIWEI, SONG, KUNYUAN
Publication of US20220081405A1 publication Critical patent/US20220081405A1/en
Application granted granted Critical
Publication of US11618741B2 publication Critical patent/US11618741B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/322,3-Dihydro derivatives, e.g. flavanones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present disclosure provides a method for preparing diselenide compound. A polar solvent is added to a dihydroflavonol compound, heated to 80° C.˜100° C., kept for 40˜50 minutes, then the base in the amount of 0.4˜1.0 times the amount of the dihydroflavonol compound is added and reacted at 80° C.˜100° C. for 5˜60 minutes, then selenium dioxide in the amount of 0.6˜1.2 times the amount of dihydroflavonol compounds at 80° C.˜100° C. The diselenide compound of the dihydroflavonol compound is obtained by reacting at a temperature of 80° C.˜100° C. for 30˜150 minutes. The method of the present disclosure has mild reaction, low pollution, does not require an anhydrous and oxygen-free environment, and is suitable for large-scale industrial production.

Description

    BACKGROUND OF THE INVENTION Technical Field of the Invention
  • The present disclosure relates to the technical field of organic synthesis, and specifically relates to a method for preparing diselenide compound.
  • Background
  • Selenium is a trace element necessary for the human body with various biological activities such as anti-oxidation, anti-cancer, anti-cancer, protection of bone marrow hematopoiesis, and delaying aging, and also has detoxifying effects on some heavy metal elements (such as mercury, arsenic, silver, etc.). There are two sources of selenium intake in the human body, one is inorganic and one is organic. Inorganic selenium generally refers to sodium selenite and sodium selenate, including yeast selenium and malt selenium with significant inorganic selenium residues. Inorganic selenium has greater toxicity and is not easily absorbed, making it unsuitable for human and animal use. Organic selenium includes simple selenoethers, diselenoethers and oxides of organic selenium. Compared with inorganic selenium, organic selenium has the characteristics of high bioavailability, strong biological activity, low toxicity and low environmental pollution. The organic selenium compounds synthesized in recent years, such as selenized chitosan, selenoproteins, selenopolysaccharides, selenized carrageenan, selenized tea polyphenols and other selenium small molecules or biomacromolecular compounds, are significantly higher than the corresponding compounds without selenization in terms of biological activities such as anti-tumor, treatment of cardiovascular diseases, anti-aging and improving the immunity of the body. Plant-active selenium is a permitted source of selenium for humans and animals. The synthesis of organoselenium compounds with high biological activity and low toxicity using the unique chemical and biological properties of selenium has been one of the current hot spots in pharmaceutical research.
  • Diselenide molecules in organic selenium contain selenium-selenium bonds, most of which have very important biological activities, such as anti-oxidation, anti-virus, anti-cancer, and anti-cancer effects, and have broad application prospects in the field of medicine. They are also an important organic synthesis reagent, and they also have broad application prospects in the field of organic synthesis. Currently, the Grignard reagent method is the classical method for the synthesis of diselenide, but the method requires strict anhydrous and oxygen-free operating conditions and low temperature environment, the process is relatively cumbersome, the yield is not high, and it is also not suitable for substrates with functional groups such as carbonyl and nitro. The hydrazine hydrate reduction method can prepare diselenyl ethers in a simpler way, but the high temperature conditions limit the method to prepare only dihydrocarbon diselenyl ethers, which are not suitable for the preparation of diselenyl ethers containing functional groups. Transition metal catalysis, which was first reported by Singh et al. in 2010, was able to obtain high yield diselenide by reacting aryl halide with monoselenide at 90° C. for 1 hour under nitrogen protection with nano-copper oxide as catalyst and DMSO as solvent and KOH as base. The reaction uses nitrogen protection, toxic organic solvents and harsh reaction conditions. The rest of the methods basically involve the synthesis of a compound containing a selenium and then reacting to produce diselenide. For example, selenocarbonyl compounds are synthesized first, and then diselenyl ethers are synthesized. All these selenium transfer reagents are difficult to prepare and their applications are limited.
  • Patent CN 103191121 B discloses a method for synthesizing an anti-tumor drug bis(quinolin-4-yl)diselenide. Among them are used sodium diselenide, potassium diselenide or lithium diselenide reagents, which need to be prepared with sodium borohydride (NaBH4) under oxygen-free conditions. The reaction of sodium borohydride is very intense, difficult to control, requires ice bath cooling, and is not easily produced on a large scale. The reaction of sodium diselenide with and 4-chloroquinoline also has to be reacted under anhydrous conditions, which are harsh.
  • SUMMARY OF INVENTION
  • The present disclosure is carried out to solve the above problems, and aims to provide a method for preparing diselenide compound with mild reaction, low pollution, no need for anhydrous and oxygen-free environment, and suitable for large-scale industrial production.
  • The present disclosure provides a method for preparing diselenide compound, which includes steps of: adding polar solvent to dihydroflavonol compound, heating to 80° C.˜100° C., and keeping for 40˜50 minutes; then adding base in the amount of 0.4˜1.0 times the amount of the dihydroflavonol compound, reacting for 5˜60 minutes at a temperature of 80° C.˜100° C.; then adding selenium dioxide in the amount of 0.6˜1.2 times the amount of the dihydroflavonol compound, reacting for 30˜150 minutes at a temperature of 80° C.˜100° C.; and obtaining diselenide compound of dihydroflavonol compound. The reaction equation is shown as below:
  • Figure US20220081405A1-20220317-C00001
  • Further, the method provided by the present disclosure for preparing diselenide compound also include the feature that the dihydroflavonol compound has the general formula as below:
  • Figure US20220081405A1-20220317-C00002
  • wherein R1 is —H, —OH, CH3O—, CH3CH2O—, (CH3)3CO—, C6H6CH2O—, a variety of glycosides and so on; R2 is —H, —OH, CH3O—, CH3CH2O—, (CH3)3CO—, C6H6CH2O—, a variety of glycosides and so on; R4 is —H, —OH, CH3O—, CH3CH2O—, (CH3)3CO—, C6H6CH2O—, a variety of glycosides and so on; R5 is —H, —OH, CH3O—, CH3CH2O—, (CH3)3CO—, C6H6CH2O—, a variety of glycosides and so on; R6 is —H, —OH, CH3O—, CH3CH2O—, (CH3)3CO—, C6H6CH2O—, a variety of glycosides and so on.
  • Further, the method for preparing diselenide compound provided by the present disclosure also have the feature that the polar solvent is water or methanol or ethanol.
  • Further, the method for preparing diselenide compound provided by the present disclosure also have the feature that the dihydroflavonol compound includes the racemate, 2S,3S isomer, and 2R,3R isomer of the dihydroflavonol compound. The 2S,3S isomer of the dihydroflavonol compound has the general formula as below:
  • Figure US20220081405A1-20220317-C00003
  • The general formulas of the 2R,3R isomers of dihydroflavonol compound is as follows:
  • Figure US20220081405A1-20220317-C00004
  • Further, in the method for preparing diselenide compound provided by the present disclosure also have the feature that the diselenide compound is obtained by naturally cooling to room temperature after the reaction is completed, adjusting the pH value of the reaction solution to 3˜6.5, extracting, separating by column chromatography, and lyophilizing.
  • The present disclosure provides the following advantages:
  • The method for preparing diselenide compound involved in the present disclosure has mild reaction conditions and is carried out below 100° C., does not require an anhydrous and oxygen-free environment, and the reaction is stable and easy to control; the preparation process has little pollution, simple post-treatment, and simple operation; the raw materials are cheap and easy to obtain, suitable for large-scale industrial production.
  • BREIF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a 1H nuclear magnetic resonance (NMR) spectrum of the product in Example 1 of the present disclosure;
  • FIG. 2 is a 13C nuclear magnetic resonance (NMR) spectrum of the product in Example 1 of the present disclosure;
  • FIG. 3 is a mass spectrum of the product in Example 1 of the present invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • In order to make the technical means, creative features, achieved purpose and efficacy realized by the present disclosure easy to understand, the method of preparing diselenide compound of the present disclosure is specified below in conjunction with the embodiments.
  • EXAMPLE 1
  • In this embodiment, dihydromyricetin was selected as the dihydroflavonol compound, which has the following general formula:
  • Figure US20220081405A1-20220317-C00005
  • 22.5 g of dihydromyricetin was added into a four-necked flask (specification 500 mL), 200 mL of water was added, heated to 80° C., and kept for 45 minutes. 2.81 g of sodium hydroxide was added, and reacted for 10 minutes under the temperature being controlled at 80° C., and 7.80 g of selenium dioxide was added and reacted for 70 minutes under the temperature being controlled at 80° C., and then the reaction was complete. Then, the heating was turned off, the pH was adjusted to 3˜6.5 with hydrochloric acid after naturally cooling to room temperature, and methanol was used for extraction. Dimyricetin-based diselenide product was obtained by lyophilizing after column chromatography separation, the yield was 8.63%.
  • EXAMPLE 2
  • In this embodiment, dihydromyricetin was selected as the dihydroflavonol compound, which has the following general formula:
  • Figure US20220081405A1-20220317-C00006
  • 15 g of dihydromyricetin was added into a four-necked flask (specification 500 mL), 200 mL of water was added, heated to 90° C., and kept for 45 minutes. 0.75 g of sodium hydroxide was added, and reacted for 60 minutes under the temperature being controlled at 90° C., and 4.16 g of selenium dioxide was added and reacted for 70 minutes under the temperature being controlled at 90° C., and then the reaction was completed. Then, the heating was turned off, the pH was adjusted to 3-6.5 with hydrochloric acid after naturally cooling to room temperature after, and methanol was used for extraction. Dimyricetin-based diselenide product was obtained by lyophilizing after column chromatography separation, the yield was 10.26%.
  • EXAMPLE 3
  • In this embodiment, dihydromyricetin is selected as the dihydroflavonol compound, which has the following general formula:
  • Figure US20220081405A1-20220317-C00007
  • 22.5 g of dihydromyricetin was added into a four-necked flask (specification 500 mL), 200 mL of water was added, heated to 100° C., and kept for 45 minutes. 2.53 g of sodium hydroxide was added and reacted for 40 minutes under the temperature being controlled at 100° C., and 9.36 g of selenium dioxide was added and reacted for 30 minutes under the temperature being controlled at 100° C., and then the reaction was complete. Then, the heating was turned off, the pH was adjusted to 3˜6.5 with hydrochloric acid after naturally cooling to room temperature, and methanol was used for extraction. Dimyricetin-based diselenide product was obtained by lyophilizing after column chromatography separation, the yield was 9.86%.
  • EXAMPLE 4
  • In this embodiment, dihydromyricetin was selected as the dihydroflavonol compound, which has the following general formula:
  • Figure US20220081405A1-20220317-C00008
  • 22.5 g of dihydromyricetin was added into a four-necked flask (specification 500 mL), 200 mL of water was added, heated to 90° C., and kept for 40 minutes. 1.69 g of sodium hydroxide was added and reacted for 20 minutes under the temperature being controlled at 90° C., and 6.24 g of selenium dioxide was added and reacted for 60 minutes under the temperature being controlled at 90° C., and then the reaction was complete. Then, the heating was turned off, the pH was adjusted to 3˜6.5 with hydrochloric acid after naturally cooling to room temperature, and methanol was used for extraction. Dimyricetin-based diselenide product was obtained by lyophilizing after column chromatography separation, the yield was 20.2%.
  • EXAMPLE 5
  • In this embodiment, dihydromyricetin was selected as the dihydroflavonol compound, which has the following general formula:
  • Figure US20220081405A1-20220317-C00009
  • 22.5 g of dihydromyricetin was added into a four-necked flask (specification 500 mL), 200 mL of water was added, heated to 90° C., and kept for 50 minutes. 2.36 g of sodium hydroxide was added and reacted for 50 minutes under the temperature being controlled at 90° C., and 6.24 g of selenium dioxide was added and reacted for 80 minutes under the temperature being controlled at 90° C., and then the reaction was complete. Then, the heating was turned off, the pH was adjusted to 3˜6.5 with hydrochloric acid after naturally cooling to room temperature, and methanol was used for extraction. Dimyricetin-based diselenide product was obtained by lyophilizing after column chromatography separation, the yield was 21.75%.
  • EXAMPLE 6
  • In this embodiment, dihydromyricetin was selected as the dihydroflavonol compound, which has the following general formula:
  • Figure US20220081405A1-20220317-C00010
  • 22.5 g of dihydromyricetin was added into a four-necked flask (specification 500 mL), 200 mL of water was added, heated to 95° C., and kept for 45 minutes. 4.05 g of sodium tert-butoxide was added and reacted for 20 minutes under the temperature being controlled at 95° C., and 4.69 g of selenium dioxide was added and reacted for 70 minutes under the temperature being controlled at 95° C., and then the reaction was complete. Then, the heating was turned off, the pH was adjusted to 3˜6.5 with hydrochloric acid after naturally cooling to room temperature, and methanol was used for extraction. Dimyricetin-based diselenide product was obtained by lyophilizing after column chromatography separation, the yield was 13%
  • EXAMPLE 7
  • In this embodiment, dihydromyricetin was selected as the dihydroflavonol compound, which has the following general formula:
  • Figure US20220081405A1-20220317-C00011
  • 22.5 g of dihydromyricetin was added into a four-necked flask (specification 500 mL), 200 mL of water was added, heated to 90° C., and kept for 45 minutes. 4.05 g of sodium tert-butoxide was added and reacted for 5 minutes under the temperature being controlled at 90° C., and 6.24 g of selenium dioxide was added and reacted for 150 minutes under the temperature being controlled at 90° C., and then the reaction was complete. Then, the heating was turned off, the pH was adjusted to 6˜6.5 with hydrochloric acid after naturally cooling to room temperature, and methanol was used for extraction. Dimyricetin-based diselenide product was obtained by lyophilizing after column chromatography separation, the yield was 38%.
  • The products obtained in the above seven embodiments were analyzed by NMR and mass (MS) spectrometry, respectively. All of them were verified to be dimyricetin-based diselenide. Only the MS spectrum, 1H NMR spectrum and 13C spectrum measured in Example 1 are listed below.
  • According to the 1H NMR spectrum shown in FIG. 1, the 1H NMR spectrum data of the product are as follows:
  • 1H NMR (400 MHZ, DMSO-d6): δ 12.73(s,1H), 10.7(s,1H) 9.15(s,1H), 8.93 (S,2H), 8.68(s, 1H), 7.26 (S,2H), 6.08(s,1H).
  • According to the 13C NMR spectrum shown in FIG. 2, the data of the 13C NMR spectrum of the product is as follows:
  • 13C NMR (400 MHZ, DMSO-d6): δ 175.95, 166.25, 162.39, 156.95, 147.55, 145.87, 145.87, 136.30, 136.30, 121.63, 107.97, 107.97, 103.67, 98.14, 95.00.
  • According to the MS spectrum shown in FIG. 3, the highest molecular ion peak is 790.887, and selenium has multiple isotope peaks.
  • From the information provided by the 1H NMR spectrum, 13C NMR spectrum and MS spectrum, it can be seen that the product obtained is dimyricetin-based diselenide.
  • EXAMPLE 8
  • In this embodiment, dihydroflavonol was selected as the dihydroflavonol compound, which has the following general formula:
  • Figure US20220081405A1-20220317-C00012
  • 22.5 g of dihydroflavonol was added into a four-necked flask (specification 500 mL), 200 mL of 30% methanol was added, heated to 90° C., and kept for 45 minutes. 3.62 g of sodium hydroxide was added and reacted for 40 minutes under the temperature being controlled at 90° C., and 9.24 g of selenium dioxide was added and reacted for 70 minutes under the temperature being controlled at 90° C., and then the reaction was complete. Then, the heating was turned off, the pH was adjusted to 5˜6 with hydrochloric acid after naturally cooling to room temperature, and methanol was used for extraction. Dihydroflavonol diselenide product was obtained by lyophilizing after column chromatography separation, the yield was 12.6%.
  • The resulting products were analyzed by NMR and mass spectrometry, respectively, and the analysis confirmed that the product is dihydroflavonol diselenide.
  • The method for preparing diselenide compound related to the present disclosure is not limited to the scope of specific embodiments. The above content is only a basic description of the present disclosure, and any equivalent transformations made based on the technical solutions of the present disclosure shall fall within the scope of protection of the present disclosure.

Claims (5)

1. A method for preparing diselenide compound, comprising steps of:
adding polar solvent to dihydroflavonol compound, heating to 80° C.˜100° C., and keeping for 40˜50 minutes;
then adding base in the amount of 0.4˜1.0 times the amount of the dihydroflavonol compound, reacting for 5˜60 minutes at a temperature of 80° C.˜100° C.;
then adding selenium dioxide in the amount of 0.6˜1.2 times the amount of the dihydroflavonol compound, reacting for 30˜150 minutes at a temperature of 80° C.˜100° C.; and
obtaining the diselenide compound of the dihydroflavonol compound.
2. The method for preparing diselenide compound according to claim 1, wherein the dihydroflavonol compound has the general formula below:
Figure US20220081405A1-20220317-C00013
wherein R1 is —H, —OH, CH3O—, CH3CH2O—, (CH3)3CO—, C6H6CH2O—, a variety of glycosides; R2 is —H, —OH, CH3O—, CH3CH2O—, (CH3)3CO—, C6H6CH2O—, a variety of glycosides; R4 is —H, —OH, CH3O—, CH3CH2O—, (CH3)3CO—, C6H6CH2O—, a variety of glycosides; R5 is —H, —OH, CH3O—, CH3CH2O—, (CH3)3CO—, C6H6CH2O—, a variety of glycosides; R6 is —H, —OH, CH3O—, CH3CH2O—, (CH3)3CO—, C6H6CH2O—, a variety of glycosides.
3. The method for preparing diselenide compound according to claim 1, wherein the polar solvent is water or methanol or ethanol.
4. The method for preparing diselenide compound according to claim 1, wherein the dihydroflavonol compound comprises racemates, 2S,3S isomers, and 2R,3R isomers of the dihydroflavonol compound.
5. The method for preparing diselenide compound according to claim 1, wherein the diselenide compound is obtained by naturally cooling to room temperature after the reaction is completed, adjusting the pH value of the reaction solution to 3˜6.5, extracting, separating by column chromatography, and lyophilizing.
US17/290,894 2020-04-30 2020-06-18 Method for preparing diselenide compound Active 2040-07-24 US11618741B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010363063.9 2020-04-30
CN202010363063.9A CN111454240B (en) 2020-04-30 2020-04-30 Process for preparing diselenide compounds
PCT/CN2020/096834 WO2021217825A1 (en) 2020-04-30 2020-06-18 Method for preparing diselenide compound

Publications (2)

Publication Number Publication Date
US20220081405A1 true US20220081405A1 (en) 2022-03-17
US11618741B2 US11618741B2 (en) 2023-04-04

Family

ID=71677869

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/290,894 Active 2040-07-24 US11618741B2 (en) 2020-04-30 2020-06-18 Method for preparing diselenide compound

Country Status (3)

Country Link
US (1) US11618741B2 (en)
CN (1) CN111454240B (en)
WO (1) WO2021217825A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112451514A (en) * 2020-11-26 2021-03-09 江西农业大学 Dihydromyricetin nano-selenium and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025387A (en) * 1996-07-25 2000-02-15 Dong A Pharmaceutical Co., Ltd. Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease
US20140323745A1 (en) * 2013-04-25 2014-10-30 Shanghai Ai Qi Ecological Technology Co., Ltd. Polyphenolic selenium compound having functional group of alkali metal ion and selenium complex

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102627614B (en) * 2012-03-29 2014-06-25 鲁东大学 Diquinazoline diselenide compound as well as preparation method and bioactivity thereof
CN103191121B (en) * 2013-04-22 2015-09-23 鲁东大学 Two (quinazoline-4-base) diselenide compound is preparing the purposes in cancer therapy drug
CN105130864B (en) 2015-07-27 2016-09-21 扬州大学 A kind of method synthesizing diselenide
CN110627761A (en) * 2019-10-12 2019-12-31 上海尹胜咨询管理合伙企业(有限合伙) Method for synthesizing myricetin
CN112479959A (en) 2020-12-14 2021-03-12 温州大学 Synthesis method of diselenide compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025387A (en) * 1996-07-25 2000-02-15 Dong A Pharmaceutical Co., Ltd. Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease
US20140323745A1 (en) * 2013-04-25 2014-10-30 Shanghai Ai Qi Ecological Technology Co., Ltd. Polyphenolic selenium compound having functional group of alkali metal ion and selenium complex

Also Published As

Publication number Publication date
US11618741B2 (en) 2023-04-04
CN111454240A (en) 2020-07-28
CN111454240B (en) 2023-05-16
WO2021217825A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
Kalinowska et al. Spectroscopic, thermogravimetric and biological studies of Na (I), Ni (II) and Zn (II) complexes of quercetin
CN104496846A (en) Preparation method of water-soluble fluorescent probe for specifically recognizing aluminum ions and application of water-soluble fluorescent probe
US11618741B2 (en) Method for preparing diselenide compound
Chiang et al. Improving free radical scavenging activity of soy isoflavone glycosides daidzin and genistin by 3′-hydroxylation using recombinant Escherichia coli
Teng et al. Antifungal agents: design, synthesis, antifungal activity and molecular docking of phloroglucinol derivatives
Zhou et al. Kilogram-scale production of selenized glucose
Li et al. Synthesis and biological activity of isoflavone derivatives from chickpea as potent anti-diabetic agents
CN109232476B (en) Method for preparing N-phenyl-3-morpholine propionamide
Matsia et al. Chromium flavonoid complexation in an antioxidant capacity role
Havránková et al. Antioxidative activity of 1, 3, 5-triazine analogues incorporating aminobenzene sulfonamide, aminoalcohol/phenol, piperazine, chalcone, or stilbene motifs
CN113150004A (en) Compound A3, preparation method thereof and application thereof as pranoprofen impurity
CN109369608B (en) Method for preparing benzo-1, 3-oxathiolane hexadiene-4-imine
CN109180591A (en) A kind of stable isotope labeling reagent and preparation method thereof
Corbi et al. Synthesis, spectroscopic characterization and biological analysis of a new palladium (II) complex with methionine sulfoxide
CN101348411A (en) Preparation of 2-alkyl anthracene derivative
CN109917054B (en) Method for improving detection sensitivity of gibberellin in crop sample
CN107880063A (en) A kind of synthetic method of dauricine
CN104334561B (en) compound JK12A and preparation thereof
Simijonović et al. Coumarin N-Acylhydrazone Derivatives: Green Synthesis and Antioxidant Potential—Experimental and Theoretical Study
CN101302236B (en) Novel method for synthesizing antineoplastic medicine nedaplatin
CN111777518A (en) Synthetic preparation method of phenylethanolamine A labeled by stable isotope
CN105646617A (en) Method for preparing tulathromycin
CN115819488B (en) 24, 31-hydrogenated pachymic acid, preparation method and application thereof
CN111039887A (en) Stable isotope labeled furaltadone metabolite and synthetic method thereof
KR20140054800A (en) Methods of preparing a 1-deoxy-1-(2-hydroxyethyl amino)-d-glucitol and miglitol

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: SHANGHAI SPARK PHARMACEUTICAL CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SONG, KUNYUAN;CHEN, WEIWEI;REEL/FRAME:056182/0365

Effective date: 20210323

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCF Information on status: patent grant

Free format text: PATENTED CASE